Clinical Trial Update: Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ [Phase 2]

View source ↗

Summary

Phase 2 maintenance trial evaluating tegafur-uracil in patients with resected squamous cell carcinoma of the oral cavity; study status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Oral Cavity

Drugs mentioned

• Tegafur-Uracil (tegafur-uracil)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Squamous Cell Carcinoma of Oral Cavity | Phase 2 | Status: UNKNOWN